P164 Cutaneous Toxicities Occurring During Amivantamab Treatment: The Experience of a Single Large Specialist Institution
June 2026
in “
British Journal of Dermatology
”
Studysummary This study reported that dermatological adverse events are common in patients treated with amivantamab for non-small cell lung cancer, often impacting quality of life and requiring treatment modifications.
Automatically generated from the study's abstract, not written by a person, and not a review of the full paper. Not medical advice or a treatment recommendation. Read the original study, and consult a qualified healthcare professional before changing treatment. Full disclaimer
Read the full study on academic.oup.com →